Related Experiment Videos
Meningococcal vaccine--do some children experience side effects?
1Department of Health, Auckland.
Insights
Following meningococcal meningitis vaccination, some children experienced temporary neurological symptoms like weakness and sensory issues. These short-term effects, though uncommon, warrant further investigation in pediatric vaccine safety studies.
Area of Science:
- Pediatric Neurology
- Vaccine Safety
- Immunology
Background:
- Group A meningococcal meningitis outbreaks necessitate public health interventions.
- Mass vaccination campaigns require robust monitoring for adverse events.
Purpose of the Study:
- To investigate the incidence and nature of adverse clinical events following a large-scale meningococcal meningitis vaccination campaign in children.
- To assess neurological symptoms reported post-vaccination.
Main Methods:
- Retrospective analysis of 546 reported adverse events and 40 specialist pediatric assessments after immunizing 130,000 children.
- Categorization of reported symptoms including fever, rash, headache, and neurological signs.
Main Results:
- 152 cases of fever, 85 of local reactions, and 63 of systemic symptoms (headache, stiff neck, myalgia) were reported.
- 92 reports indicated peripheral nerve involvement, including weakness, paraesthesia, and dysaesthesia; none were permanent.
- 25 cases showed agreement between parental reports and pediatric assessments.
Conclusions:
- Temporary neurological symptoms, including peripheral nerve involvement, may occur following meningococcal vaccination.
- The study highlights the importance of monitoring for both common and rare adverse events in mass immunization programs.
- Adverse publicity may influence symptom reporting, but short-term neurological effects post-vaccination appear plausible.
Abstract:
In order to stop an outbreak of group A meningococcal meningitis, 130,000 Auckland children were immunised. During the month following vaccination there were 546 reports of unusual clinical events reported by parents and practitioners, together with 40 specialist paediatric assessments of children presenting with neurological symptoms. In 25 of these latter there was complete agreement between the history as presented by parents in the initial telephone report and the paediatrician's subsequent summarised history. Of the 546 reports, 217 either had too little detail for an assessment or the symptoms were clearly attributable to other causes. Of the remaining reports, there were 152 cases of fever with or without other symptoms; 85 were of rash and local reactions within 24h of vaccination; 63 reports were of headache, stiff neck and myalgia within 48h of vaccination. There were 92 reports of apparent peripheral nerve involvement, including 80 reports of unexplained weakness and 57 reports of paraesthesia or dysaesthesia. Both motor and sensory symptoms occurred in some children; none were permanent. The effects of adverse publicity during the campaign on the genesis of some symptoms is acknowledged, but the possibility that short term neurological symptoms occur after vaccination seems likely and has not been previously reported.